viral
respiratori
tract
infect
lung
transplant
recipi
may
sever
three
consecut
winterspr
season
symptomat
lung
transplant
recipi
suspect
respiratori
viral
infect
asymptomat
patient
investig
presenc
respiratori
virus
either
nasopharyng
aspir
bronchoalveolar
lavag
sampl
taken
differ
time
transplant
whole
asymptomat
symptomat
patient
posit
human
metapneumoviru
hmpv
patient
influenza
viru
patient
b
patient
respiratori
syncyti
viru
patient
human
coronaviru
patient
human
parainfluenza
viru
patient
rhinoviru
patient
patient
coinfect
respiratori
virus
infect
sequenti
respiratori
virus
bronchoalveolar
lavag
sampl
hmpv
predomin
far
virus
respons
posit
specimen
wherea
virus
present
nasopharyng
aspir
compar
rate
rtpcr
detect
posit
examin
larg
superior
monoclon
antibodi
detect
posit
sampl
addit
hcmv
detect
associ
respiratori
viru
hcmvposit
patient
found
high
concentr
dna
copiesml
patient
hcmvposit
bronchoalveolar
lavag
sampl
pneumonia
coinfect
sequenti
infect
hcmv
respiratori
virus
significantli
frequent
patient
acut
reject
steroid
treatment
conclus
respiratori
tract
infect
lung
transplant
recipi
associ
one
respiratori
virus
ii
hmpv
larg
predomin
bronchoalveolar
lavag
symptomat
lung
transplant
recipi
thu
suggest
caus
role
lower
respiratori
tract
infect
iii
rtpcr
appear
method
choic
detect
respiratori
virus
lung
transplant
recipi
iv
high
hcmv
load
bronchoalveolar
lavag
risk
factor
viral
pneumonia
suggest
measur
intervent
control
viral
infect
j
med
virol
key
word
human
metapneumoviru
human
cytomegaloviru
lung
transplant
recipi
respiratori
tract
viral
infect
nasopharyng
aspir
bronchoalveolar
lavag
revers
transcriptionpolymeras
chain
reaction
rtpcr
number
respiratori
virus
includ
human
respiratori
syncyti
viru
hrsv
human
parainfluenza
virus
hpiv
type
influenza
virus
b
human
adenovirus
hadv
known
common
caus
communityacquir
respiratori
tract
infect
children
adult
also
recogn
import
pathogen
pediatr
adult
lung
transplant
recipi
wend
et
al
bridg
et
al
krinzman
et
al
palmer
et
al
garantzioti
et
al
vilchez
et
al
vilchez
et
al
vilchez
et
al
bill
et
al
overal
incid
infect
caus
differ
respiratori
virus
report
vari
case
per
patient
cumul
cohort
lung
transplant
recipi
reach
global
incid
consid
hrsv
influenzavirus
b
hpiv
hadv
infect
altogeth
ohori
et
al
matar
et
al
vilchez
et
al
vilchez
et
al
bill
et
al
studi
conduct
use
poorli
sensit
method
viru
detect
virus
human
coronavirus
hcov
rhinovirus
recent
identifi
human
metapneumoviru
hmpv
investig
respiratori
virus
commonli
caus
mild
respiratori
infect
immunocompet
subject
often
respons
sever
infect
lower
respiratori
tract
lung
transplant
recipi
marx
et
al
glezen
et
al
hall
patient
type
infect
report
predispos
highgrad
bronchiol
obliteran
syndrom
rel
risk
bill
et
al
respect
number
retrospect
studi
perform
led
conflict
conclus
bill
et
al
mccurdi
et
al
khalifah
et
al
howev
number
virus
investig
sensit
methodolog
use
frequenc
respiratori
sampl
collect
number
respiratori
episod
per
patient
variabl
partial
consid
entir
overlook
differ
studi
addit
pathogen
role
human
cytomegaloviru
hcmv
infect
bronchoalveolar
lavag
remain
defin
bailey
et
al
riis
et
al
westal
et
al
well
relationship
bronchiol
obliteran
kroshu
et
al
husain
et
al
khalifah
et
al
tamm
et
al
present
studi
nasopharyng
aspir
bronchoalveolar
lavag
sampl
examin
entir
cohort
lung
transplant
recipi
follow
institut
presenc
absenc
acut
respiratori
symptom
show
respiratori
virus
major
pathogen
symptomat
patient
ii
hmpv
predomin
posit
bronchoalveolar
lavag
sampl
iii
pcrbase
method
larg
superior
direct
fluoresc
antibodi
stain
cell
cultur
respiratori
viru
detect
iv
high
hcmv
load
repres
risk
factor
viral
pneumonia
novemb
may
prospect
surveil
studi
upper
lower
respiratori
tract
viral
infect
conduct
institut
lung
transplant
recipi
involv
patient
acut
respiratori
symptom
patient
asymptomat
affect
nonrespiratori
clinic
symptom
fever
alon
reject
followup
restrict
winterspr
season
novemb
may
viral
test
request
differ
time
transplant
includ
patient
immedi
posttranspl
period
well
patient
within
year
transplant
patient
classifi
symptomat
presenc
least
one
follow
rhinorrhea
sore
throat
cough
sputum
dyspnea
reduc
lung
function
chest
xray
abnorm
whole
patient
lower
patient
upper
respiratori
tract
infect
nasopharyng
aspir
n
taken
patient
complain
symptom
upper
respiratori
tract
without
reduc
lung
function
onset
acut
infect
appropri
followup
bronchoalveolar
lavag
sampl
n
taken
whenev
possibl
presenc
lower
airway
involv
addit
bronchoalveolar
lavag
sampl
n
obtain
asymptomat
patient
routin
followup
sampl
surveil
bronchoscopi
bronchoalveolar
lavag
specimen
examin
routin
presenc
viral
bacteri
fungal
agent
radiograph
function
data
examin
parallel
final
patient
symptomat
asymptomat
test
time
season
repeat
episod
respiratori
tract
infect
repeat
surveil
bronchoscopi
group
posit
patient
underw
followup
sampl
whenev
feasibl
neg
sampl
obtain
patient
maintain
tripledrug
immunosuppress
corticosteroid
azathioprin
cyclosporin
patient
present
persist
acut
reject
progress
loss
graft
function
cyclosporin
replac
tacrolimu
andor
azathioprin
mycophenol
mophetil
absenc
graft
reject
cyclosporin
steroid
progress
reduc
within
month
surgeri
immunosuppress
regimen
modifi
substanti
episod
acut
respiratori
infect
viral
coinfect
defin
respiratori
infect
result
simultan
identif
one
viru
sampl
sequenti
viral
infect
includ
subsequ
infect
subject
least
one
viru
differ
detect
upon
first
episod
respiratori
infect
season
detect
viru
sever
week
consid
evid
protract
infect
whole
lung
transplant
recipi
examin
period
total
specimen
bronchoalveolar
lavag
sampl
nasopharyng
aspir
upon
collect
follow
homogenis
secret
nasopharyng
aspir
divid
four
aliquot
use
direct
fluoresc
antibodi
stain
respiratori
cell
inocul
onto
cell
cultur
viru
isol
molecular
assay
storag
backup
sampl
two
diagnost
approach
use
viru
identif
respiratori
sampl
immunolog
approach
aim
viru
identif
follow
stain
monoclon
antibodi
cell
nasopharyng
aspir
inocul
cell
cultur
molecular
approach
base
use
pcrbase
assay
aim
amplifi
nucleic
acid
respiratori
sampl
virus
detect
monoclon
antibodi
influenza
virus
b
hpiv
hrsv
hadv
addit
hcov
group
ii
hmpv
type
b
rhinovirus
detect
rtpcr
hcov
group
sequenc
hmpv
type
sequenc
phylogenet
analysi
rovida
et
al
pool
monoclon
antibodi
influenza
virus
b
hpiv
hrsv
hadv
well
individu
monoclon
antibodi
virus
chemicon
intern
inc
temecula
ca
use
viru
identif
direct
fluoresc
antibodi
stain
respiratori
cell
nasopharyng
aspir
trypsin
cell
shell
vial
convent
cell
cultur
zavattoni
et
al
rovida
et
al
rtpcr
assay
optim
detect
least
input
plasmid
copi
primer
hcov
group
ii
select
publish
protocol
poutanen
et
al
well
primer
rhinovirus
steining
et
al
wherea
primer
hmpv
type
b
gene
n
f
design
origin
genbank
publish
viru
sequenc
sarasini
et
al
press
amplif
product
clone
plasmid
vector
ta
clone
kit
invitrogen
carlsbad
ca
prepar
quantit
standard
rovida
et
al
nuclisen
iso
kit
lyon
franc
use
extract
nucleic
acid
rt
pcr
reaction
mostli
perform
real
time
report
rovida
et
al
pcr
product
examin
agaros
gel
new
realtim
pcr
techniqu
hcmv
dna
quantit
clinic
sampl
develop
briefli
use
abi
prism
tm
primer
express
tm
softwar
appli
biosystem
foster
citi
ca
follow
primer
pair
select
amplif
fragment
cmvsmf
cmvsmr
addit
taqman
probe
label
end
fluorochrom
end
mgbnfq
quencher
probe
also
select
cmvsm
oligonucleotid
synthes
purifi
label
appli
biosystem
uk
warrington
cheshir
uk
realtim
pcr
perform
use
abi
prism
sequenc
detect
system
appli
biosystem
foster
citi
ca
standard
reagent
taqman
univers
master
mix
appli
biosystem
uk
hcmv
dna
coamplifi
heterolog
dna
taqman
exogen
intern
posit
control
vic
tm
warrington
cheshir
uk
use
specif
primer
probe
verifi
absenc
pcr
inhibitor
parallel
serial
amount
plasmid
carri
hcmv
target
sequenc
extern
quantif
standard
follow
activ
taq
polymeras
min
reaction
cycl
time
sec
sec
standard
curv
construct
automat
abi
prism
instrument
base
signal
extern
quantit
standard
quantit
hcmv
dna
clinic
sampl
obtain
interpol
method
develop
recent
base
stimul
patient
peripher
blood
mononuclear
cell
hcmvinfect
autolog
immatur
dendrit
cell
use
determin
hcmvspecif
interferongproduc
tcell
cytokin
flow
cytometri
lozza
et
al
cutoff
discrimin
posit
neg
hcmvspecif
cell
cellsml
blood
tcell
subpopul
preemptiv
therapi
hcmv
infect
lung
transplant
recipi
guid
antigenemia
assay
gerna
et
al
report
comparison
distribut
frequenc
differ
paramet
studi
perform
use
pearson
chisquar
test
three
consecut
winterspr
season
examin
overal
incid
lung
transplant
recipi
posit
respiratori
virus
patient
howev
patient
popul
divid
two
subgroup
accord
presenc
absenc
respiratori
symptom
overal
incid
patient
posit
respiratori
virus
symptomat
patient
control
asymptomat
lung
transplant
recipi
shown
figur
along
entir
studi
period
three
patient
infect
influenza
viru
two
influenza
viru
b
two
hpiv
two
hrsv
four
hmpv
five
rhinovirus
two
hcov
four
patient
coinfect
five
sequenti
season
infect
respiratori
virus
addit
hcmv
detect
sporad
intermitt
patient
see
season
circul
singl
respiratori
virus
includ
coinfect
sequenti
infect
hrsv
repres
viru
length
excret
among
patient
examin
season
show
persist
excret
viru
hrsv
median
durat
excret
day
group
patient
newonset
clinic
episod
differenti
continu
previou
episod
basi
appear
new
viru
patient
respiratori
viral
infect
recov
acut
episod
either
spontan
follow
administr
antivir
therapi
particular
three
patient
sever
lower
respiratori
tract
infect
caus
influenza
virus
treat
zanamivir
day
complet
rapid
resolut
acut
respiratori
symptom
addit
four
patient
sever
acut
hrsv
infect
treat
ribavirin
day
resolut
symptom
howev
one
patient
symptom
resolut
associ
hrsv
disappear
bronchoalveolar
lavag
three
patient
hrsv
persist
nasopharynx
resolut
symptom
patient
acut
respiratori
infect
associ
episod
acut
chronic
reject
preferenti
associ
reject
episod
upper
lower
respiratori
tract
infect
observ
overal
incid
bronchoalveolar
lavag
sampl
posit
respiratori
virus
sampl
significantli
p
lower
nasopharyng
aspir
sampl
howev
differ
signific
p
fig
distribut
differ
respiratori
virus
hmpv
significantli
higher
incid
bronchoalveolar
lavag
sampl
nasopharyng
aspir
p
respiratori
virus
repres
compar
rate
upper
lower
respiratori
tract
fig
bronchoalveolar
lavag
respiratori
viru
infect
associ
bacteri
fungal
infect
three
lung
transplant
recipi
one
patient
coinfect
hmpv
fumigatu
one
patient
hmpv
p
aeruginosa
one
patient
influenza
viru
p
aeruginosa
find
relev
hcmv
report
whole
sampl
examin
posit
respiratori
virus
rtpcr
wherea
detect
monoclon
antibodi
either
nasopharyng
aspir
cell
cultur
tabl
specimen
detect
monoclon
antibodi
miss
rtpcr
wherea
mani
rtpcrposit
sampl
miss
monoclon
antibodi
p
hcmv
detect
respiratori
secret
lung
transplant
recipi
hcmv
infect
associ
anoth
respiratori
viral
pathogen
four
patient
present
singl
infecti
agent
patient
local
hcmv
infect
viru
detect
bronchoalveolar
lavag
nasopharyng
aspir
sampl
season
incid
vari
greatli
rang
sampl
sampl
sampl
detail
relev
patient
coinfect
sequenti
infect
includ
respiratori
virus
hcmv
report
tabl
ii
whole
incid
multipl
simultan
sequenti
season
infect
lung
transplant
recipi
acut
reject
antireject
steroid
treatment
patient
neither
reject
steroid
treatment
differ
statist
signific
p
quantit
hcmv
dna
respiratori
secret
show
high
amount
viral
dna
copi
ml
lower
respiratori
tract
detect
bronchoalveolar
lavag
sampl
lung
transplant
recipi
tabl
iii
patient
part
group
patient
respiratori
infect
caus
common
respiratori
virus
three
patient
admit
intens
care
unit
within
month
transplant
fever
dyspnoea
reduc
lung
function
radiolog
sign
pneumonia
two
patient
bacteri
infect
p
aeruginosa
aureu
associ
hcmv
treat
antibiot
patient
hcmv
infect
system
local
hcmv
load
blood
reach
peak
greater
leukocyt
examin
cutoff
preemptiv
therapi
thu
requir
initi
antivir
treatment
patient
hcmv
infect
local
viru
detect
blood
thu
patient
treat
follow
guidelin
adopt
depart
howev
three
patient
recov
within
month
longterm
control
hcmv
infect
blood
bronchoalveolar
lavag
attain
like
due
fact
patient
high
viral
load
detect
blood
lung
month
transplant
initi
control
antivir
treatment
ganciclovir
prior
subsequ
develop
effici
tcell
immun
respons
hand
patient
hcmv
load
lung
prompt
steroid
treatment
due
acut
reject
occur
month
transplant
control
hcmv
specif
immun
respons
reconstitut
month
surgeri
tabl
iii
two
patient
bronchiol
obliteran
syndrom
emerg
month
report
episod
pneumonia
major
conclus
emerg
studi
respiratori
virus
detect
major
lung
transplant
recipi
respiratori
symptom
ii
coinfect
sequenti
infect
detect
fairli
high
proport
symptomat
patient
respiratori
virus
includ
hcmv
iii
rate
respiratori
viru
detect
compar
bronchoalveolar
lavag
nasopharyng
aspir
symptomat
patient
iv
howev
hmpv
infect
significantli
higher
bronchoalveolar
lavag
sampl
compar
nasopharyng
aspir
v
respiratori
virus
detect
less
frequent
monoclon
antibodi
compar
rtpcr
vi
hcmv
detect
frequent
respiratori
tract
lung
transplant
recipi
howev
associ
high
viral
load
bronchoalveolar
lavag
patient
lower
respiratori
tract
infect
first
point
result
studi
strongli
support
conclus
detect
respiratori
virus
upper
lower
respiratori
tract
lung
transplant
recipi
mostli
associ
presenc
upper
lower
respiratori
symptom
addit
incid
viral
coinfect
sequenti
infect
lung
transplant
recipi
seem
substanti
differ
report
previou
studi
gener
popul
repres
fair
proport
respiratori
infect
coira
et
al
van
den
hoogen
et
al
van
den
hoogen
et
al
rovida
et
al
howev
antireject
treatment
appear
signific
risk
factor
occurr
multipl
infect
compar
frequenc
detect
respiratori
virus
bronchoalveolar
lavag
nasopharyng
aspir
sampl
indic
viral
respiratori
infect
involv
lower
well
upper
respiratori
tract
lung
transplant
recipi
particular
current
studi
significantli
higher
incid
hmpv
infect
bronchoalveolar
lavag
surpris
compar
nasopharyng
aspir
sampl
respiratori
virus
detect
compar
rate
two
site
although
respiratori
viru
van
den
hoogen
et
al
report
pathogen
immunocompromis
patient
present
find
suggest
need
care
monitor
hmpv
infect
lung
transplant
recipi
molecular
method
rtpcr
adjust
detect
hmpv
subtyp
sarasini
et
al
press
hmpvspecif
monoclon
antibodi
recent
develop
laboratori
complement
altern
rtpcr
diagnosi
hmpv
infect
percival
et
al
garbino
et
al
diagnost
standpoint
studi
immunolog
approach
detect
respiratori
virus
use
monoclon
antibodi
appear
much
less
sensit
molecular
approach
use
rtpcr
former
detect
sampl
posit
rtpcr
monoclon
antibodi
may
provid
test
result
within
hr
nasopharyng
aspir
collect
hand
direct
fluoresc
antibodi
stain
appli
reliabl
bronchoalveolar
lavag
specimen
rapid
viral
isol
shell
vial
cultur
follow
monoclon
antibodi
identif
test
choic
use
appropri
sensit
method
rapid
detect
respiratori
virus
crucial
import
light
advanc
antivir
therapi
potenti
threat
pandem
influenza
studi
use
zanamivir
three
patient
lower
respiratori
tract
infect
caus
influenza
virus
use
ribavirin
four
patient
lower
respiratori
infect
caus
hrsv
contribut
resolv
acut
episod
hcmv
detect
respiratori
specimen
presenc
nasopharyng
aspir
signific
clinic
presenc
bronchoalveolar
lavag
seem
correl
clinic
symptom
histolog
detect
hcmvspecif
inclus
bodi
transbronchi
biopsi
howev
hcmv
infect
bronchoalveolar
lavag
must
consid
quantit
term
predict
reliabl
biopsyproven
hcmv
lung
infect
bailey
et
al
riis
et
al
westal
et
al
presenc
hcmv
dna
level
predetermin
threshold
valu
may
indic
either
high
risk
emerg
presenc
overt
lower
respiratori
tract
diseas
thu
suggest
time
initi
antivir
treatment
full
dosag
prophylaxi
protocol
use
reduc
ganciclovir
dosag
found
prevent
hcmv
infect
detect
bronchoalveolar
lavag
sampl
westal
et
al
well
known
organ
local
hcmv
infect
may
dissoci
system
infect
presenc
viru
blood
aid
patient
lung
transplant
recipi
gerna
et
al
sanchez
et
al
westal
et
al
henc
need
monitor
hcmv
blood
bronchoalveolar
lavag
sampl
view
start
treatment
even
presenc
high
viru
load
bronchoalveolar
lavag
alon
recent
westal
et
al
determin
dna
level
copiesml
bronchoalveolar
lavag
sampl
predictor
hcmv
inclus
lung
allograft
lung
transplant
recipi
addit
investig
specul
hcmv
load
greater
copiesml
like
associ
specif
diseas
hcmv
pneumon
sanchez
et
al
three
patient
cohort
high
hcmv
load
bronchoalveolar
lavag
local
resolut
hcmv
infect
achiev
reconstitut
specif
tcell
immun
chronolog
occur
absenc
antivir
treatment
patient
follow
time
start
ganciclovir
treatment
full
dosag
patient
final
respiratori
viru
hcmv
infect
suggest
potenti
cofactor
pathogenesi
bronchiol
obliteran
syndrom
howev
mention
literatur
data
respect
conflict
kroshu
et
al
husain
et
al
khalifah
et
al
tamm
et
al
westal
et
al
whether
respiratori
viru
hcmv
infect
respiratori
tract
may
play
caus
role
pathogenesi
bronchiol
obliteran
investig
multicent
largescal
prospect
studi
period
determin
clinic
patholog
function
condit
respiratori
tract
patient
receiv
lung
transplant
